Fig. 4: PD-L1 on cDC1s is upregulated during antigen presentation by IFN-γ.

a WT B6 mice were inoculated with 5 × 10⁵ MC38-EGFP cells. After tumor established, tumors and draining LNs (n = 8 mice) were isolated on day 14. EGFP⁺ cells on cDC1 and cDC2 were measured by flow cytometry. b PD-L1 levels on total and EGFP⁺ cDC1s in draining LN were shown. c PD-L1 levels on EGFP⁻ and EGFP⁺ DCs in tumor tissues were shown (n = 6 mice). **p = 0.0035. d BMDCs were co-culture with MC38 or MC38-EGFP cells for 24 h. Percentages of EGFP⁺ cells were shown (n = 3). e PD-L1 levels on EGFP⁻ and EGFP⁺ BMDCs were shown (n = 4 cells, except FMO n = 3). ***p = 0.0003. f, g WT B6 mice were inoculated with 5 × 10⁵ MC38-EGFP cells. Mice were treated with IgG, anti-IFNAR1, anti-IFN-γ, or anti-CD8 to block each pathway. Tumor tissues were collected and analyzed on day 14. f Percentages of EGFP⁺ cDC1s (n = 7 mice) were shown. g PD-L1 levels on EGFP⁻ and EGFP⁺ cDC1s (n = 3 mice) were measured by flow cytometry. *p = 0.0489. Data are shown as mean ± SEM and are representative of two independent experiments (b, c–e, and g) or pool of two independent experiments (a and f). n.s., not significant; *p < 0.05; **p < 0.01 determined by unpaired two-tailed Student’s t test. Source data are provided as a Source Data file.